StockData

Orchestra BioMed Holdings, Inc. (OBIO) stock

OBIONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 9/30
$6.97−0.15 (-2.11%)

Close on Nov 17, 2026Market cap $418.93MP/E –Yield –

Orchestra BioMed operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Orchestra BioMed's operating cash flow for the twelve months ending Jun 30, 2026 was -$58.32M. For fiscal 2025 it was -$48.96M. The highest annual figure on record is -$272.36K in fiscal 2021.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$48.96M–
FY2024Dec 31, 2024-$50.56M–
FY2023Dec 31, 2023-$46.13M–
FY2022Dec 31, 2022-$29.29M–
FY2021Dec 31, 2021-$272.36K–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$19.33M–
Q1 FY2026Mar 31, 2026-$22.17M–
Q4 FY2025Dec 31, 2025-$2.27M–
Q3 FY2025Sep 30, 2025-$14.55M–
Q2 FY2025Jun 30, 2025-$15.53M–
Q1 FY2025Mar 31, 2025-$16.62M–
Q4 FY2024Dec 31, 2024-$13.54M–
Q3 FY2024Sep 30, 2024-$13.70M–
Q2 FY2024Jun 30, 2024-$10.21M–
Q1 FY2024Mar 31, 2024-$13.11M–
Q4 FY2023Dec 31, 2023-$10.97M–
Q3 FY2023Sep 30, 2023-$10.28M–
Q2 FY2023Jun 30, 2023-$10.49M–
Q1 FY2023Mar 31, 2023-$14.38M–
Q4 FY2022Dec 31, 2022-$8.74M–
Q3 FY2022Sep 30, 2022-$7.26M–
Q2 FY2022Jun 30, 2022-$7.97M–
Q1 FY2022Mar 31, 2022-$5.32M–
Q4 FY2021Dec 31, 2021-$28.84K–
Q3 FY2021Sep 30, 2021-$128.01K–
Q2 FY2021Jun 30, 2021-$39.14K–
Q1 FY2021Mar 31, 2021-$76.37K–

More Orchestra BioMed figures

See a number that looks wrong?